Reflex Medical Device App Used for Study on Opiate Withdrawal, Military Concussion

High-tech company BrightLamp’s device is being used in clinical studies funded by the NIH and DoD

WEST LAFAYETTE, Ind. Third-party research groups and organizations have developed . A smartphone app called overturned As a tool to help diagnose medical conditions such as concussion and opiate withdrawal.

Brightlamp CEO Kurtis Sluss said the reflex has been used in more than 200 clinics, with more than 90,000 tests conducted so far. More than 30,000 patients have benefited from rapid neurological evaluation of the reflex. Brightlamp has commercialized the app.

The reflex is an autonomic vitals assessment tool embedded in pupillometry, which measures how much and how rapidly the pupil of the eye changes in size in response to a stimulus. The device takes a digital video recording of the eye to measure a response called the pupillary light reflex. The user holds the camera up to the eye and taps the smartphone screen, and a light is flashed to initiate a response from the pupil. According to the U.S. Food and Drug Administration, the reflex is a Class I 510(k) exemption regulated medical device.

slus said opioidA data science company, independently determined that the reflex is a predictor of opiate withdrawal, which could be used to combat the opioid epidemic in the US.

“As part of a study funded by the National Institutes of Health, clinical researchers to determine its efficacy as a stand-alone and reflex for combination evaluation addressing opiate addiction.” rigorously evaluated,” Sluss said. “Reflex will help those involved in the opioid epidemic receive fast, reliable and accurate information. Now, addiction recovery experts can use this cognitive biomarker to better understand and optimize addiction recovery.”

Christopher Ivonko, opioid research study coordinator and doctoral candidate in the University of North Carolina Wilmington’s Department of Psychology, said reflex pupillometry measures derived from standard self-report and observational measures during a study to evaluate the extent of opioid withdrawal. performed better than Ivanko said the metric was significantly associated with the time elapsed since a patient’s last opioid dose.

“Accurate and reliable quantification of opioid withdrawal is of critical importance to guide dosing decisions in the provision of medically assisted treatment of opioid use disorder,” Ivonko said. “The Reflex App addresses the accessibility concern of traditional pupillometry devices and has the potential to positively impact the opioid epidemic by providing clinicians with actionable data to maintain patients and ultimately improve treatment outcomes. “

Sluss said the clinical findings also showed that the reflex was useful in diagnosing concussion. 2021 Published Study, Independent, validated research is being presented in 2022.

“This prompted medical researchers at the University of Maryland, in partnership with the US Department of Defense, to use the reflex in a two-year clinical trial to evaluate 1,200 soldiers who suffered a brain injury,” Sluss said. has done.”

“Reflex was touted by researchers at the University of Maryland as the highest-scoring concussion clinical decision-support tool among many other leading concussion tools on the market. This preliminary evaluation shows how powerful the reflex can be in a military setting.”

Sluss said other third-party studies are underway, opening up a range of opportunities for reflex users.

“Our goal is to become the standard tool in the investigation of cognitive health regardless of disease,” Sluss said. “These parallel studies are showing positive results and proving what we already knew: the eyes are an important access point for the management of brain-related injury and disease.”

Brightlamp has opened an investment in its company through StartEngine, a regulated crowdfunding organization, to support the next wave of reflex development and market growth. The campaign can be found online http://www.startengine.com/reflex,

BrightLamp for Reflex plans to continue to enhance data interpretation for clinical decision support based on independent data published by reflex users.

“We’ve built an excellent reflex community, and we’re collectively excited at how useful this easy-to-use medical app is becoming,” Sluss said.

Sluss has received commercialization guidance from Purdue Foundry, an entrepreneurship and commercialization center, is located at the Convergence Center for Innovation and Collaboration in the Discovery Park District at Purdue, adjacent to the Purdue University campus. His company is now part of Purdue Foundry’s double down experiment, which includes high-growth businesses.

About Brightlamp

Brightlamp is an Indiana-based health care technology company that specializes in frontier computer vision methods. As recognized by experts such as Donald Kuratko of Indiana University, the company develops innovative neurological breakthrough methods and applies them to mobile solutions to aid the advancement of cognitive health care.

BrightLamp’s flagship patented technology monitors the eye’s response to light so that medical professionals can obtain more accurate and consistent neurological information in seconds via a mobile device. The iPhone and iPad Name Apple Inc. are registered trademarks of. For more information, see https://reflexapp.io/,

About Purdue Foundry

Purdue Foundry is an entrepreneurship and commercialization center whose professionals help Purdue innovators build startups. Purdue Foundry is managed by the Purdue Research Foundation, which received the 2019 Innovation and Economic Prosperity University Award for Place from the Association of Public and Land-Grant Universities. Contact Purdue Foundry [email protected],

Author/Media Contact: Steve Martin, [email protected]

Source: kurtis slus, [email protected]

Christopher Ivanko, [email protected]